期刊
CANCER JOURNAL
卷 15, 期 5, 页码 386-394出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e3181b9c5ec
关键词
efficacy; measurement; overall survival; progression-free survival; surrogate
类别
资金
- Novartis Oncology
In clinical trials of oncology drugs, overall survival (OS) is a direct measure of clinical efficacy and is considered the gold standard primary efficacy end point. The purpose of this study was to discuss the difficulties in using OS as a primary efficacy end point in the setting of evolving cancer therapies. We suggest that progression-free survival is an appropriate efficacy end point in many types of cancer, specifically those for which CS is expected to be prolonged and for which subsequent treatments are expected to affect OS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据